Parkman Healthcare Partners’s Cogent Biosciences COGT Stock Holding History

Parkman Healthcare Partners’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.85M	Buy	+100,126	New	+$3.7M	0.4%	68
2024 Q1	–	Sell	-96,837	Closed	-$569K	–	104
2023 Q4	$569K	Sell	96,837 -96,800	-50%	-$742K	0.08%	87
2023 Q3	$1.89M	Buy	193,637 +7,855	+4%	+$93.2K	0.35%	78
2023 Q2	$2.2M	Buy	185,782 +3,886	+2%	+$44.6K	0.38%	73
2023 Q1	$1.96M	Buy	181,896 +40,314	+28%	+$516K	0.43%	57
2022 Q4	$1.64M	Sell	141,582 -95,115	-40%	-$1.18M	0.44%	61
2022 Q3	$3.53M	Sell	236,697 -52,053	-18%	-$713K	1%	37
2022 Q2	$2.6M	Buy	+288,750	New	+$1.97M	0.96%	36

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Parkman Healthcare Partners's COGT Position: Q1 2026 in Review

Parkman Healthcare Partners opened a new position in Cogent Biosciences (COGT) in Q1 2026: 100,126 shares worth $3.85M. The stake represents 0.4% of the portfolio and ranks #68 among its holdings. This is a return to the name: Parkman Healthcare Partners previously reported a position in COGT as recently as Q4 2023.

Parkman Healthcare Partners first reported a position in COGT in Q2 2022 and has held it in 8 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Parkman Healthcare Partners held 100,126 shares of Cogent Biosciences worth $3.85M as of Q1 2026.
Cogent Biosciences was a new Parkman Healthcare Partners position in Q1 2026.
Cogent Biosciences made up 0.4% of Parkman Healthcare Partners's portfolio in Q1 2026, its #68 holding.
Parkman Healthcare Partners first reported a position in Cogent Biosciences in Q2 2022 and has held it in 8 quarters since.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.